The role of rituximab and chemotherapy in aggressive b-cell lymphoma: A preliminary report of dose-adjusted EPOCH-R

Seminars in Oncology

Volumn 29, Issue 1 SUPPL. 2, 2002, Pages 41-47

  Wilson, Wyndham H ^a   Gutierrez, Martin ^a   O'Connor, Paula ^a   Frankel, Stanley ^a   Jaffe, Elaine ^a   Chabner, Bruce A ^a   Grossbard, Michael L ^b  

^a UNIVERSITY OF MARYLAND   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; B CELL LYMPHOMA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; MALE; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS;

EID: 0036178668     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.30151     Document Type: Conference Paper

References (37)

1. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas
2. Modulation of multidrug resistance (MDR) in hematological malignancies
3. Reversal of multidrug resistance in hematological malignancies
4. Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy
5. Clinical reversal of multidrug resistance
6. The role of MDR- 1 in refractory lymphoma
7. Role of P-glycoprotein in human natural killer-like cell line-mediated cytotoxicity
8. Glutathione S-transferase and glutathione peroxidase are essential in the early stage of adriamycin resistance before P-glycoprotein overexpression in HOB1 lymphoma cells
9. ATP-dependent transport of aflatoxin B1 and its glutathione conjugates by the product of the multidrug resistance protein (MRP) gene
10. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate
11. Mechanisms of altered sequestration and efflux of chemotherapeutic drugs by multidrug-resistant cells
12. Drug resistance mediated by cellular stress response to the microenvironment of solid tumors
13. p53 and chemosensitivity
14. Multidrug resistance protein MRP1, glutathione, and related enzymes. Their importance in acute myeloid leukemia
15. Cell cycle control and cancer chemotherapy
16. Checkpoints of dueling dimers foil death wishes
17. Dysregulation of apoptosis in cancer
18. Relationship between DNA cross-links, cell cycle and apoptosis in Burkitt's lymphoma cell lines differing in sensitivity to nitrogen mustard
19. Preclinical and clinical development of cyclin-dependent kinase modulators
20. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies
21. Anti-CD20 antibody mediated apoptosis is dependent on caspase 3 activation
22. Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes
23. CD20: A regulator of cell-cycle progression of B lymphocytes
24. Association of tyrosine and serine kinases with the B cell surface antigen CD20. Induction via CD20 of tyrosine phosphorylation and activation of phospholipase C-gamma 1 and PLC phospholipase C-gamma 2
25. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphomas
26. Dose-adjusted EPOCH-rituximab (EPOCH-R): An effective regimen in poor prognosis aggressive B-cell lymphoma
27. The role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: An 8 year follow-up study of EPOCH
28. Dose-adjusted EPOCH chemotherapy in untreated large B-cell lymphomas: A novel pharmacodynamic-based regimen
29. Phase II study of dose-adjusted EPOCH-rituximab in untreated high risk large B-cell lymphomas
30. A predictive model for aggressive non-Hodgkin's lymphoma
31. ESHAP-An effective chemotherapy regimen in refractory and relapsing lymphoma: A 4-year follow-up study
32. Chemotherapy sensitization by rituximab: Presentation of two case studies
33. MabThera (rituximab) plus CHOP is superior to CHOP alone in elderly patients with diffuse large B-cell lymphomas (DLCL): Interim results of a randomized GELA trial
34. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated aggressive non-Hodgkin's lymphoma
35. Bone marrow involvement by non-Hodgkin's lymphoma: The clinical significance of morphologic discordance between the lymph node and bone marrow
36. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
37. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs